Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 2/2016

08.03.2016 | Review Article

Accelerated Premalignant Polyposis and Second Colon Cancers: Incriminating Immunosuppression, Radiotherapy, and Systemic Chemotherapy Agents

verfasst von: Frank J. Senatore, Shruti Murali, Constantin A. Dasanu

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Cancer survivors are known to be at increased risk for second primary cancers. In addition, immunosuppression and previous cancer treatments such as radiotherapy and systemic chemotherapy are linked with increased risk of both colonic adenomas and adenocarcinomas.

Aim

We performed a systematic review searching for manuscripts discussing second colon cancers, accelerated polyposis, immunosuppression, radiation, and chemotherapy. We sought to identify a link between immunosuppression and increased risks specific to premalignant polyposis and second colon cancers.

Findings

We identified multiple studies demonstrating associations between radiotherapy, systemic chemotherapy, and immunosuppression with a higher propensity for second colon adenomas and adenocarcinomas. When compared to the general population, these risks were more profound and the rate at which these second malignancies developed was significantly increased.

Conclusions

We believe that timing for colonoscopic surveillance in these patients should be different from the general population in order to identify promptly these rapidly progressive neoplasms. Screening for second malignancies should be considered early after remission of the primary cancer is documented, especially when a prolonged survival or a cure is anticipated. We also recommend consideration be given to increasing the frequency of colonoscopy in these cohorts. Future studies are required in order to establish the optimal time interval for surveillance colonoscopy in these high-risk individuals.
Literatur
1.
Zurück zum Zitat Curtis RE, Freedman DM, Ron E, et al. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH Pub. No. 05-5302. Bethesda: National Cancer Institute; 2006. Curtis RE, Freedman DM, Ron E, et al. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH Pub. No. 05-5302. Bethesda: National Cancer Institute; 2006.
4.
Zurück zum Zitat Senatore FJ, Dasanu CA. Synchronous gastric and ampullary adenocarcinomas in a hairy cell leukemia patient treated with pentostatin eight years prior. J Oncol Pharm Pract. 2015. Senatore FJ, Dasanu CA. Synchronous gastric and ampullary adenocarcinomas in a hairy cell leukemia patient treated with pentostatin eight years prior. J Oncol Pharm Pract. 2015.
5.
Zurück zum Zitat Nakatsuka H, Shimizu Y, Yamamoto T, et al. Colorectal cancer incidence among atomic bomb survivors, 1950–1980. J Radiat Res. 1992;33(4):342–61.CrossRefPubMed Nakatsuka H, Shimizu Y, Yamamoto T, et al. Colorectal cancer incidence among atomic bomb survivors, 1950–1980. J Radiat Res. 1992;33(4):342–61.CrossRefPubMed
7.
Zurück zum Zitat Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst. 2012;104(5):357–70.CrossRefPubMedPubMedCentral Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst. 2012;104(5):357–70.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Nottage K, McFarlane J, Krasin M, et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol. 2012;30(20):2552–8.CrossRefPubMed Nottage K, McFarlane J, Krasin M, et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol. 2012;30(20):2552–8.CrossRefPubMed
9.
Zurück zum Zitat Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer paints: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354–65.CrossRefPubMed Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer paints: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354–65.CrossRefPubMed
10.
Zurück zum Zitat Abdel-Wahab M, Reis IM, Wu J, et al. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. Urology. 2009;74(4):866–71.CrossRefPubMed Abdel-Wahab M, Reis IM, Wu J, et al. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. Urology. 2009;74(4):866–71.CrossRefPubMed
11.
Zurück zum Zitat Goodsell D. The molecular perspective: double-stranded DNA breaks. Oncologist. 2005;10(5):361–2.CrossRefPubMed Goodsell D. The molecular perspective: double-stranded DNA breaks. Oncologist. 2005;10(5):361–2.CrossRefPubMed
12.
Zurück zum Zitat Birdwell SH, Hancock SL, Varghese A, et al. Gastrointestinal cancer after treatment of Hodgkin’s disease. Int J Radiat Biol Phys. 1997;37(1):67–73.CrossRef Birdwell SH, Hancock SL, Varghese A, et al. Gastrointestinal cancer after treatment of Hodgkin’s disease. Int J Radiat Biol Phys. 1997;37(1):67–73.CrossRef
13.
Zurück zum Zitat Van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487–97.PubMed Van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487–97.PubMed
14.
Zurück zum Zitat Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18(3):498–509.PubMed Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18(3):498–509.PubMed
15.
Zurück zum Zitat Razavi P, Rand KA, Cozen W, et al. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction novel therapeutics. Blood Cancer J. 2013;28(3), e121.CrossRef Razavi P, Rand KA, Cozen W, et al. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction novel therapeutics. Blood Cancer J. 2013;28(3), e121.CrossRef
16.
Zurück zum Zitat Kaur A, Dasanu CA. Rapidly progressive colonic dysplasia/neoplasia in a series of treated lung cancer patients: is paclitaxel involved? J Oncol Pharm Pract. 2013;19(1):82–5.CrossRefPubMed Kaur A, Dasanu CA. Rapidly progressive colonic dysplasia/neoplasia in a series of treated lung cancer patients: is paclitaxel involved? J Oncol Pharm Pract. 2013;19(1):82–5.CrossRefPubMed
17.
Zurück zum Zitat Atassi T, Thuluvath PJ. Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol. 2003;37(1):72–3.CrossRefPubMed Atassi T, Thuluvath PJ. Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol. 2003;37(1):72–3.CrossRefPubMed
18.
Zurück zum Zitat Trivedi MH, Agrawal S, Muscato MS, et al. High grade, synchronous colon cancers after renal transplantation: were immunosuppressive drugs to blame? Am J Gastroenterol. 1999;94(11):3359–61.CrossRefPubMed Trivedi MH, Agrawal S, Muscato MS, et al. High grade, synchronous colon cancers after renal transplantation: were immunosuppressive drugs to blame? Am J Gastroenterol. 1999;94(11):3359–61.CrossRefPubMed
19.
Zurück zum Zitat Aigner F, Boeckle E, Albright J, et al. Malignancies of the colorectum and anus in solid organ recipients. Transpl Int. 2007;20(6):497–504.CrossRefPubMed Aigner F, Boeckle E, Albright J, et al. Malignancies of the colorectum and anus in solid organ recipients. Transpl Int. 2007;20(6):497–504.CrossRefPubMed
20.
Zurück zum Zitat Danan G, Faure S, Duny Y. Prevalence of adenomatous colon polyps after liver transplantation: the level of immunosuppression makes the difference. J Hepatol. 2013;58(1):S69.CrossRef Danan G, Faure S, Duny Y. Prevalence of adenomatous colon polyps after liver transplantation: the level of immunosuppression makes the difference. J Hepatol. 2013;58(1):S69.CrossRef
21.
Zurück zum Zitat Nishihori T, Stazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer. 2008;7(4):260–6.CrossRefPubMedPubMedCentral Nishihori T, Stazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer. 2008;7(4):260–6.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am. 1993;7(2):431–45.PubMed Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am. 1993;7(2):431–45.PubMed
23.
Zurück zum Zitat Travis LB, Wahnefriend WD, Allan JM, et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289–301.CrossRefPubMed Travis LB, Wahnefriend WD, Allan JM, et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289–301.CrossRefPubMed
24.
Zurück zum Zitat Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98(1):15–25.CrossRefPubMed Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98(1):15–25.CrossRefPubMed
25.
Zurück zum Zitat Win AK, Lindor NM, Young JP, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst. 2012;104:1363–72.CrossRefPubMedPubMedCentral Win AK, Lindor NM, Young JP, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst. 2012;104:1363–72.CrossRefPubMedPubMedCentral
Metadaten
Titel
Accelerated Premalignant Polyposis and Second Colon Cancers: Incriminating Immunosuppression, Radiotherapy, and Systemic Chemotherapy Agents
verfasst von
Frank J. Senatore
Shruti Murali
Constantin A. Dasanu
Publikationsdatum
08.03.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 2/2016
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9813-9

Weitere Artikel der Ausgabe 2/2016

Journal of Gastrointestinal Cancer 2/2016 Zur Ausgabe

Letter to the Editor

Pancreatic Cystic Mass

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.